NCT03534804View on ClinicalTrials.gov

Cabozantinib Plus Pembrolizumab as First-Line Therapy for Cisplatin-Ineligible Advanced Urothelial Carcinoma

PHASE2CompletedINTERVENTIONAL
Enrollment

37

Participants

Timeline

Start Date

September 18, 2018

Primary Completion Date

August 2, 2023

Study Completion Date

April 15, 2024

Conditions
Metastatic Urothelial CarcinomaBladder Cancer
Interventions
DRUG

Cabozantinib

Cabozantinib is administered at 40 mg oral daily

DRUG

Pembrolizumab

Pembrolizumab will be administered at a fixed dose of 200mg intravenously every 3 weeks.

Trial Locations (3)

30322

Winship Cancer Institute, Emory University, Atlanta

33612

Moffitt Cancer Center, Tampa

84112

Huntsman Cancer Institute, Salt Lake City

Sponsors

Collaborators (1)

Exelixis
All Listed Sponsors
collaborator

Exelixis

INDUSTRY

lead

University of Utah

OTHER

NCT03534804 - Cabozantinib Plus Pembrolizumab as First-Line Therapy for Cisplatin-Ineligible Advanced Urothelial Carcinoma | Biotech Hunter | Biotech Hunter